Addison ’s disease Drugs Market- Global Industry Analysis and Forecast (2024 – 2030)


Addison's disease Drugs Market is expected to reach US$ 3.95 Bn. at a CAGR of 7.23 % during the forecast period 2030. The rising prevalence of Addison's disease coupled with advancements in drug development targeting adrenal insufficiency are key factors propelling the growth of Addison's disease drugs market, expected to register a CAGR of 7.23% by 2030.

Addison's disease is a rare condition in which the two outer layers of cells in the adrenal glands (adrenal cortex) are unable to produce enough cortisol and aldosterone. Addison's disease drugs are medications used to treat people who have adrenal insufficiency. These medications assist in replenishing insufficient hormones generated by the adrenal glands. The Addison's Disease drugs market has been growing continuously as the condition's incidence has increased substantially all across the world as well as increasing advances in pharmaceutical research and development. The market is expected to grow significantly, as more effective and focused therapies are developed during the forecast period.

According to the MMR Addison's Disease drugs report, the Addison's Disease drugs market is expected to grow substantially as global knowledge and diagnosis of the ailment increase, providing attractive potential prospects for Addison's Disease drugs manufacturers throughout the forecast period. In addition, increased patient awareness, development and progress in therapies, and the emergence of modern healthcare organizations are all major factors driving the need for Addison's disease drugs. likewise, increased incidences of Addison's disease and an increase in research and development initiatives conducted by various pharmaceutical firms contribute to the growth of Addison's disease drugs market.
Addisons disease Drugs MarketTo know about the Research Methodology :- Request Free Sample Report

Addison’s Disease Drugs Market Dynamics:

Addison’s disease is a rare adrenal gland hormonal disorder which affects approximately less than 1 million people around the world. The growth of the Addison’s disease drugs market can attribute to various factors such as growing awareness about the disease and the available diagnosis for the same, reformulation of drugs, special drug designations and several reimbursement policies.

Further R&D is developing advanced treatments in which adrenocortical stem cells will be combined with immunomodulatory treatment resulting in the modification of the immune system.

Addison’s Disease Drugs Market Segment Analysis:

According to the studies, in the diagnosis segment of the market, blood tests are the prime source used for diagnosing the Addison’s disease. This is because blood tests correctly point out the levels of sodium, potassium, cortisol, and adrenocorticotropic hormone (ACTH) which are responsible for the production of adrenal hormones. Next in line is the ACTH Stimulation test as ACTH signals the adrenal to produce hormones and this test ensures that there is no secondary adrenal inefficiency.

Addison’s Disease Drugs Market Regional Analysis:

The Addison’s disease drug market in the US and other countries of North America is huge and is growing constantly. This attributes to the presence of well-developed healthcare infrastructure, awareness about the disease, and favorable reimbursement policies. Europe ranks second in Addison’s disease drug market due to the increase in the expenditure on the health sector. On contrary, the Middle East and Africa account for the least of the Addison’s disease drug market in the world.

Addison’s Disease Drugs Market Competitive Landscape:

The competitive landscape section in Addison’s Disease Drugs Market offers a deep dive into the profiles of the leading players operating in the global market landscape. It offers captivating insights on the key developments, differential strategies, and other crucial aspects about the companies having a stronghold in the Addison’s Disease Drugs Market. In November 2013, Shire acquired shares of ViroPharma making both financially strong.

The objective of the report is to present a comprehensive analysis of the Global Addison’s Disease Market including all the stakeholders of the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the Market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Addison’s Disease Drugs Market dynamics, structure by analyzing the Market segments and projects the Global Addison’s Disease Drugs Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Addison’s Disease Market make the report investor’s guide.

Addison’s Disease Drugs Market Scope :Inquire before buying






Addison’s Disease Drugs Market




Report Coverage
Details




Base Year:
2023
Forecast Period:
2024-2030




Historical Data:
2018 to 2023
Market Size in 2023:
US $ 2.42 Bn.




Forecast Period 2024 to 2030 CAGR:
7.23 %
Market Size in 2030:
US $ 3.95 Bn.




 Segments Covered:
by Diagnosis
Laboratory Tests
Image Testing




by Treatment
Oral Corticosteroid
Corticosteroid Injections




by End User
Hospitals and Clinics
Diagnostic Laboratories
Other End Users






Addison's disease Drugs Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina, Columbia and Rest of South America)

Major Addison's Disease Drugs Market Players

1. Bristol-Myers Squibb Company
2. Merck & Co. Inc.
3. Novartis AG
4. Pfizer Inc.
5. Takeda Pharmaceutical Company Ltd
6. Boehringer Ingelheim International GmbH
7. Shire
8. Tocris Bioscience
9. GlaxoSmithKline
10. Lupin Pharmaceuticals Inc.
11. Abbott Laboratories
12. Amgen Limited
13. Bayer AG
14. Biogen
15. Eli Lilly and Company
16. Diurnal
17. Bio-Techne
18. Switzer Life Science
19. Recipharm
20. ViroPharma

Frequently Asked Questions:

1. Which region has the largest share in Global Addison’s disease Drugs Market?
Ans: North America region held the highest share in 2023.

2. What is the growth rate of Global Addison’s disease Drugs Market?
Ans: The Global Addison’s disease Drugs Market is growing at a CAGR of 7.23 % during forecasting period 2024-2030.

3. What is scope of the Global Market report?
Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Market?
Ans: The important key players in the Global Market are – Bristol-Myers Squibb Company, Merck & Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Ltd, Boehringer Ingelheim International GmbH, Shire, Tocris Bioscience, GlaxoSmithKline, Lupin Pharmaceuticals Inc., Abbott Laboratories, Amgen Limited & Amgen Ireland Limited, Bayer AG, Biogen, Eli Lilly and Company, Diurnal, Switzer Life science Pvt. Ltd., ViroPharma, DuoCort Pharma AB.

5. What is the study period of this Market?
Ans: The Global Market is studied from 2023 to 2030. 




Global Addison’s Disease Drugs Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Global Addison’s Disease Drugs Market Size, by Market Value (US$ Bn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators
6. Global Addison’s Disease Drugs Market Analysis and Forecast
6.1. Addison’s Disease Drugs Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Addison’s Disease Drugs Market Analysis and Forecast, By Diagnosis
7.1. Introduction and Definition
7.2. Key Findings
7.3. Addison’s Disease Drugs Market Value Share Analysis, By Diagnosis
7.4. Addison’s Disease Drugs Market Size (US$ Bn) Forecast, By Diagnosis
7.5. Addison’s Disease Drugs Market Analysis, By Diagnosis
7.6. Addison’s Disease Drugs Market Attractiveness Analysis, By Diagnosis

8. Global Addison’s Disease Drugs Market Analysis and Forecast, By Treatment
8.1. Introduction and Definition
8.2. Key Findings
8.3. Addison’s Disease Drugs Market Value Share Analysis, By Treatment
8.4. Addison’s Disease Drugs Market Size (US$ Bn) Forecast, By Treatment
8.5. Addison’s Disease Drugs Market Analysis, By Treatment
8.6. Addison’s Disease Drugs Market Attractiveness Analysis, By Treatment

9. Global Addison’s Disease Drugs Market Analysis and Forecast, By End User
9.1. Introduction and Definition
9.2. Key Findings
9.3. Addison’s Disease Drugs Market Value Share Analysis, By End User
9.4. Addison’s Disease Drugs Market Size (US$ Bn) Forecast, By End User
9.5. Addison’s Disease Drugs Market Analysis, By End User
9.6. Addison’s Disease Drugs Market Attractiveness Analysis, By End User

10. Global Addison’s Disease Drugs Market Analysis, by Region
10.1. Addison’s Disease Drugs Market Value Share Analysis, by Region
10.2. Addison’s Disease Drugs Market Size (US$ Bn) Forecast, by Region
10.3. Addison’s Disease Drugs Market Attractiveness Analysis, by Region

11. North America Addison’s Disease Drugs Market Analysis
11.1. Key Findings
11.2. North America Addison’s Disease Drugs Market Overview
11.3. North America Addison’s Disease Drugs Market Value Share Analysis, By Diagnosis
11.4. North America Addison’s Disease Drugs Market Forecast, By Diagnosis
11.4.1. Laboratory Tests
11.4.2. Image Tests
11.5. North America Addison’s Disease Drugs Market Value Share Analysis, By Treatment
11.6. North America Addison’s Disease Drugs Market Forecast, By Treatment
11.6.1. Oral Corticosteroid
11.6.2. Corticosteroid Injections
11.7. North America Addison’s Disease Drugs Market Value Share Analysis, By End User
11.8. North America Addison’s Disease Drugs Market Forecast, By End User
11.8.1. Hospitals and Clinics
11.8.2. Diagnostic Laboratories
11.8.3. Other End Users
11.9. North America Addison’s Disease Drugs Market Value Share Analysis, by Country
11.10. North America Addison’s Disease Drugs Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Addison’s Disease Drugs Market Analysis, by Country
11.12. U.S. Addison’s Disease Drugs Market Forecast, By Diagnosis
11.12.1. Laboratory Tests
11.12.2. Image Tests
11.13. U.S. Addison’s Disease Drugs Market Forecast, By Treatment
11.13.1. Oral Corticosteroid
11.13.2. Corticosteroid Injections
11.14. U.S. Addison’s Disease Drugs Market Forecast, By End User
11.14.1. Hospitals and Clinics
11.14.2. Diagnostic Laboratories
11.14.3. Other End Users
11.15. Canada Addison’s Disease Drugs Market Forecast, By Diagnosis
11.15.1. Laboratory Tests
11.15.2. Image Tests
11.16. Canada Addison’s Disease Drugs Market Forecast, By Treatment
11.16.1. Oral Corticosteroid
11.16.2. Corticosteroid Injections
11.17. Canada Addison’s Disease Drugs Market Forecast, By End User
11.17.1. Hospitals and Clinics
11.17.2. Diagnostic Laboratories
11.17.3. Other End Users
11.18. North America Addison’s Disease Drugs Market Attractiveness Analysis
11.18.1. By Diagnosis
11.18.2. By Treatment
11.18.3. By End User
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Developments

12. Europe Addison’s Disease Drugs Market Analysis
12.1. Key Findings
12.2. Europe Addison’s Disease Drugs Market Overview
12.3. Europe Addison’s Disease Drugs Market Value Share Analysis, By Diagnosis
12.4. Europe Addison’s Disease Drugs Market Forecast, By Diagnosis
12.4.1. Laboratory Tests
12.4.2. Image Tests
12.5. Europe Addison’s Disease Drugs Market Value Share Analysis, By Treatment
12.6. Europe Addison’s Disease Drugs Market Forecast, By Treatment
12.6.1. Oral Corticosteroid
12.6.2. Corticosteroid Injections
12.7. Europe Addison’s Disease Drugs Market Value Share Analysis, By End User
12.8. Europe Addison’s Disease Drugs Market Forecast, By End User
12.8.1. Hospitals and Clinics
12.8.2. Diagnostic Laboratories
12.8.3. Other End Users
12.9. Europe Addison’s Disease Drugs Market Value Share Analysis, by Country
12.10. Europe Addison’s Disease Drugs Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Addison’s Disease Drugs Market Analysis, by Country
12.12. Germany Addison’s Disease Drugs Market Forecast, By Diagnosis
12.12.1. Laboratory Tests
12.12.2. Image Tests
12.13. Germany Addison’s Disease Drugs Market Forecast, By Treatment
12.13.1. Oral Corticosteroid
12.13.2. Corticosteroid Injections
12.14. Germany Addison’s Disease Drugs Market Forecast, By End User
12.14.1. Hospitals and Clinics
12.14.2. Diagnostic Laboratories
12.14.3. Other End Users
12.15. U.K. Addison’s Disease Drugs Market Forecast, By Diagnosis
12.15.1. Laboratory Tests
12.15.2. Image Tests
12.16. U.K. Addison’s Disease Drugs Market Forecast, By Treatment
12.16.1. Oral Corticosteroid
12.16.2. Corticosteroid Injections
12.17. U.K. Addison’s Disease Drugs Market Forecast, By End User
12.17.1. Hospitals and Clinics
12.17.2. Diagnostic Laboratories
12.17.3. Other End Users
12.18. France Addison’s Disease Drugs Market Forecast, By Diagnosis
12.18.1. Laboratory Tests
12.18.2. Image Tests
12.19. France Addison’s Disease Drugs Market Forecast, By Treatment
12.19.1. Oral Corticosteroid
12.19.2. Corticosteroid Injections
12.20. France Addison’s Disease Drugs Market Forecast, By End User
12.20.1. Hospitals and Clinics
12.20.2. Diagnostic Laboratories
12.20.3. Other End Users
12.21. Italy Addison’s Disease Drugs Market Forecast, By Diagnosis
12.21.1. Laboratory Tests
12.21.2. Image Tests
12.22. Italy Addison’s Disease Drugs Market Forecast, By Treatment
12.22.1. Oral Corticosteroid
12.22.2. Corticosteroid Injections
12.23. Italy Addison’s Disease Drugs Market Forecast, By End User
12.23.1. Hospitals and Clinics
12.23.2. Diagnostic Laboratories
12.23.3. Other End Users
12.24. Spain Addison’s Disease Drugs Market Forecast, By Diagnosis
12.24.1. Laboratory Tests
12.24.2. Image Tests
12.25. Spain Addison’s Disease Drugs Market Forecast, By Treatment
12.25.1. Oral Corticosteroid
12.25.2. Corticosteroid Injections
12.26. Spain Addison’s Disease Drugs Market Forecast, By End User
12.26.1. Hospitals and Clinics
12.26.2. Diagnostic Laboratories
12.26.3. Other End Users
12.27. Rest of Europe Addison’s Disease Drugs Market Forecast, By Diagnosis
12.27.1. Laboratory Tests
12.27.2. Image Tests
12.28. Rest of Europe Addison’s Disease Drugs Market Forecast, By Treatment
12.28.1. Oral Corticosteroid
12.28.2. Corticosteroid Injections
12.29. Rest of Europe Addison’s Disease Drugs Market Forecast, By End User
12.29.1. Hospitals and Clinics
12.29.2. Diagnostic Laboratories
12.29.3. Other End Users
12.30. Europe Addison’s Disease Drugs Market Attractiveness Analysis
12.30.1. By Diagnosis
12.30.2. By Treatment
12.30.3. By End User
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Developments

13. Asia Pacific Addison’s Disease Drugs Market Analysis
13.1. Key Findings
13.2. Asia Pacific Addison’s Disease Drugs Market Overview
13.3. Asia Pacific Addison’s Disease Drugs Market Value Share Analysis, By Diagnosis
13.4. Asia Pacific Addison’s Disease Drugs Market Forecast, By Diagnosis
13.4.1. Laboratory Tests
13.4.2. Image Tests
13.5. Asia Pacific Addison’s Disease Drugs Market Value Share Analysis, By Treatment
13.6. Asia Pacific Addison’s Disease Drugs Market Forecast, By Treatment
13.6.1. Oral Corticosteroid
13.6.2. Corticosteroid Injections
13.7. Asia Pacific Addison’s Disease Drugs Market Value Share Analysis, By End User
13.8. Asia Pacific Addison’s Disease Drugs Market Forecast, By End User
13.8.1. Hospitals and Clinics
13.8.2. Diagnostic Laboratories
13.8.3. Other End Users
13.9. Asia Pacific Addison’s Disease Drugs Market Value Share Analysis, by Country
13.10. Asia Pacific Addison’s Disease Drugs Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Addison’s Disease Drugs Market Analysis, by Country
13.12. China Addison’s Disease Drugs Market Forecast, By Diagnosis
13.12.1. Laboratory Tests
13.12.2. Image Tests
13.13. China Addison’s Disease Drugs Market Forecast, By Treatment
13.13.1. Oral Corticosteroid
13.13.2. Corticosteroid Injections
13.14. China Addison’s Disease Drugs Market Forecast, By End User
13.14.1. Hospitals and Clinics
13.14.2. Diagnostic Laboratories
13.14.3. Other End Users
13.15. India Addison’s Disease Drugs Market Forecast, By Diagnosis
13.15.1. Laboratory Tests
13.15.2. Image Tests
13.16. India Addison’s Disease Drugs Market Forecast, By Treatment
13.16.1. Oral Corticosteroid
13.16.2. Corticosteroid Injections
13.17. India Addison’s Disease Drugs Market Forecast, By End User
13.17.1. Hospitals and Clinics
13.17.2. Diagnostic Laboratories
13.17.3. Other End Users
13.18. Japan Addison’s Disease Drugs Market Forecast, By Diagnosis
13.18.1. Laboratory Tests
13.18.2. Image Tests
13.19. Japan Addison’s Disease Drugs Market Forecast, By Treatment
13.19.1. Oral Corticosteroid
13.19.2. Corticosteroid Injections
13.20. Japan Addison’s Disease Drugs Market Forecast, By End User
13.20.1. Hospitals and Clinics
13.20.2. Diagnostic Laboratories
13.20.3. Other End Users
13.21. ASEAN Addison’s Disease Drugs Market Forecast, By Diagnosis
13.21.1. Laboratory Tests
13.21.2. Image Tests
13.22. ASEAN Addison’s Disease Drugs Market Forecast, By Treatment
13.22.1. Oral Corticosteroid
13.22.2. Corticosteroid Injections
13.23. ASEAN Addison’s Disease Drugs Market Forecast, By End User
13.23.1. Hospitals and Clinics
13.23.2. Diagnostic Laboratories
13.23.3. Other End Users
13.24. Rest of Asia Pacific Addison’s Disease Drugs Market Forecast, By Diagnosis
13.24.1. Laboratory Tests
13.24.2. Image Tests
13.25. Rest of Asia Pacific Addison’s Disease Drugs Market Forecast, By Treatment
13.25.1. Oral Corticosteroid
13.25.2. Corticosteroid Injections
13.26. Rest of Asia Pacific Addison’s Disease Drugs Market Forecast, By End User
13.26.1. Hospitals and Clinics
13.26.2. Diagnostic Laboratories
13.26.3. Other End Users
13.27. Asia Pacific Addison’s Disease Drugs Market Attractiveness Analysis
13.27.1. By Diagnosis
13.27.2. By Treatment
13.27.3. By End User
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Developments

14. Middle East & Africa Addison’s Disease Drugs Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Addison’s Disease Drugs Market Overview
14.3. Middle East & Africa Addison’s Disease Drugs Market Value Share Analysis, By Diagnosis
14.4. Middle East & Africa Addison’s Disease Drugs Market Forecast, By Diagnosis
14.4.1. Laboratory Tests
14.4.2. Image Tests
14.5. Middle East & Africa Addison’s Disease Drugs Market Value Share Analysis, By Treatment
14.6. Middle East & Africa Addison’s Disease Drugs Market Forecast, By Treatment
14.6.1. Oral Corticosteroid
14.6.2. Corticosteroid Injections
14.7. Middle East & Africa Addison’s Disease Drugs Market Value Share Analysis, By End User
14.8. Middle East & Africa Addison’s Disease Drugs Market Forecast, By End User
14.8.1. Hospitals and Clinics
14.8.2. Diagnostic Laboratories
14.8.3. Other End Users
14.9. Middle East & Africa Addison’s Disease Drugs Market Value Share Analysis, by Country
14.10. Middle East & Africa Addison’s Disease Drugs Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Addison’s Disease Drugs Market Analysis, by Country
14.12. GCC Addison’s Disease Drugs Market Forecast, By Diagnosis
14.12.1. Laboratory Tests
14.12.2. Image Tests
14.13. GCC Addison’s Disease Drugs Market Forecast, By Treatment
14.13.1. Oral Corticosteroid
14.13.2. Corticosteroid Injections
14.14. GCC Addison’s Disease Drugs Market Forecast, By End User
14.14.1. Hospitals and Clinics
14.14.2. Diagnostic Laboratories
14.14.3. Other End Users
14.15. South Africa Addison’s Disease Drugs Market Forecast, By Diagnosis
14.15.1. Laboratory Tests
14.15.2. Image Tests
14.16. South Africa Addison’s Disease Drugs Market Forecast, By Treatment
14.16.1. Oral Corticosteroid
14.16.2. Corticosteroid Injections
14.17. South Africa Addison’s Disease Drugs Market Forecast, By End User
14.17.1. Hospitals and Clinics
14.17.2. Diagnostic Laboratories
14.17.3. Other End Users
14.18. Rest of Middle East & Africa Addison’s Disease Drugs Market Forecast, By Diagnosis
14.18.1. Laboratory Tests
14.18.2. Image Tests
14.19. Rest of Middle East & Africa Addison’s Disease Drugs Market Forecast, By Treatment
14.19.1. Oral Corticosteroid
14.19.2. Corticosteroid Injections
14.20. Middle East & Africa Addison’s Disease Drugs Market Forecast, By End User
14.20.1. Hospitals and Clinics
14.20.2. Diagnostic Laboratories
14.20.3. Other End Users
14.21. Middle East & Africa Addison’s Disease Drugs Market Attractiveness Analysis
14.21.1. By Diagnosis
14.21.2. By Treatment
14.21.3. By End User
14.22. PEST Analysis
14.23. Key Trends
14.24. Key Developments

15. South America Addison’s Disease Drugs Market Analysis
15.1. Key Findings
15.2. South America Addison’s Disease Drugs Market Overview
15.3. South America Addison’s Disease Drugs Market Value Share Analysis, By Diagnosis
15.4. South America Addison’s Disease Drugs Market Forecast, By Diagnosis
15.4.1. Laboratory Tests
15.4.2. Image Tests
15.5. South America Addison’s Disease Drugs Market Value Share Analysis, By Treatment
15.6. South America Addison’s Disease Drugs Market Forecast, By Treatment
15.6.1. Oral Corticosteroid
15.6.2. Corticosteroid Injections
15.7. South America Addison’s Disease Drugs Market Value Share Analysis, By End User
15.8. South America Addison’s Disease Drugs Market Forecast, By End User
15.8.1. Hospitals and Clinics
15.8.2. Diagnostic Laboratories
15.8.3. Other End Users
15.9. South America Addison’s Disease Drugs Market Value Share Analysis, by Country
15.10. South America Addison’s Disease Drugs Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Addison’s Disease Drugs Market Analysis, by Country
15.12. Brazil Addison’s Disease Drugs Market Forecast, By Diagnosis
15.12.1. Laboratory Tests
15.12.2. Image Tests
15.13. Brazil Addison’s Disease Drugs Market Forecast, By Treatment
15.13.1. Oral Corticosteroid
15.13.2. Corticosteroid Injections
15.14. Brazil Addison’s Disease Drugs Market Forecast, By End User
15.14.1. Hospitals and Clinics
15.14.2. Diagnostic Laboratories
15.14.3. Other End Users
15.15. Mexico Addison’s Disease Drugs Market Forecast, By Diagnosis
15.15.1. Laboratory Tests
15.15.2. Image Tests
15.16. Mexico Addison’s Disease Drugs Market Forecast, By Treatment
15.16.1. Oral Corticosteroid
15.16.2. Corticosteroid Injections
15.17. Mexico Addison’s Disease Drugs Market Forecast, By End User
15.17.1. Hospitals and Clinics
15.17.2. Diagnostic Laboratories
15.17.3. Other End Users
15.18. Rest of South America Addison’s Disease Drugs Market Forecast, By Diagnosis
15.18.1. Laboratory Tests
15.18.2. Image Tests
15.19. Rest of South America Addison’s Disease Drugs Market Forecast, By Treatment
15.19.1. Oral Corticosteroid
15.19.2. Corticosteroid Injections
15.20. Rest of South America Addison’s Disease Drugs Market Forecast, By End User
15.20.1. Hospitals and Clinics
15.20.2. Diagnostic Laboratories
15.20.3. Other End Users
15.21. South America Addison’s Disease Drugs Market Attractiveness Analysis
15.21.1. By Diagnosis
15.21.2. By Treatment
15.21.3. By End User
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Developments

16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications, and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward Integration
16.3. Company Profiles: Key Players
16.3.1. Bristol-Myers Squibb Company
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Development Footprint
16.3.2. Bristol-Myers Squibb Company
16.3.2. Merck & Co. Inc.
16.3.3. Novartis AG
16.3.4. Pfizer Inc.
16.3.5. Takeda Pharmaceutical Company Ltd
16.3.6. Boehringer Ingelheim International GmbH
16.3.7. Shire
16.3.8. Tocris Bioscience
16.3.9. GlaxoSmithKline
16.3.10. Lupin Pharmaceuticals Inc.
16.3.11. Abbott Laboratories
16.3.12. Amgen Limited
16.3.13. Bayer AG
16.3.14. Biogen
16.3.15. Eli Lilly and Company
16.3.16. Diurnal
16.3.17. Bio-Techne
16.3.18. Switzer Life Science
16.3.19. Recipharm
16.3.20. ViroPharma
  • INQUIRE BEFORE BUYING